

**IN THE UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF ILLINOIS**

NOVO NORDISK A/S AND NOVO
NORDISK INC.,

Plaintiffs,

v.

AMERICAN HEALTH CENTER,
LTD.,

Defendant.

Case No. 24-cv-12772

COMPLAINT

Plaintiffs Novo Nordisk A/S (“NNAS”) and Novo Nordisk Inc. (“NNI”) (collectively, “Plaintiffs” or “Novo Nordisk”) file their complaint against American Health Center, Ltd. (“Defendant”) for false advertising, unfair competition, and deceptive trade practices and seek injunctive, monetary, and other relief. Plaintiffs allege as follows, on actual knowledge with respect to themselves and their own acts and on information and belief as to all other matters.

INTRODUCTION

1. Novo Nordisk is a healthcare company with a 100-year history of innovation in developing medicines to treat serious chronic diseases like diabetes and obesity.
2. The development of semaglutide is an example of Novo Nordisk’s commitment to innovation for those living with chronic diseases. Semaglutide is the foundational molecule that serves as the primary ingredient for Novo Nordisk’s three prescription-only medicines approved by the Food and Drug Administration (“FDA”): Ozempic® (semaglutide) injection and Rybelsus® (semaglutide) tablets for adults with type 2 diabetes and Wegovy® (semaglutide) injection for chronic weight management.
3. Novo Nordisk is the only company in the United States with FDA-approved medicines containing semaglutide.

4. Novo Nordisk is also the only company authorized to identify its FDA-approved semaglutide medicines using the trademarks Ozempic[®], Wegovy[®], and Rybelsus[®].

5. The FDA has not approved any generic versions of semaglutide medicines. To the contrary, the FDA has sent warning letters to companies that have claimed that their unapproved drug products have the “same active ingredient as Ozempic, Rybelsus, and Wegovy,” noting that Ozempic and Wegovy are the only “two injectable semaglutide products FDA-approved for the U.S. market.”¹

6. This action is brought pursuant to the Lanham Act, 15 U.S.C. §§ 1051 *et seq.*, related state laws, and the common law arising out of Defendant’s acts of false advertising and unfair and deceptive trade practices, and Plaintiffs’ rights in their Wegovy[®], Ozempic[®], and Rybelsus[®] marks.

7. Defendant uses, markets, and sells to patients compounded drug products that purport to contain semaglutide.

8. Even though such compounded drug products have not been evaluated by the FDA for their safety, effectiveness, or quality, Defendant falsely and misleadingly represents to patients that its products are FDA-approved or the same as, or equivalent to, Novo Nordisk’s FDA-approved semaglutide medicines.

9. Defendant’s conduct is likely to confuse and deceive patients into mistakenly believing that they are purchasing authentic Novo Nordisk medicines or medicines that have been evaluated by the FDA, studied in clinical trials, and deemed safe and effective.

¹ FDA – Warning Letter to Ozempen.com, MARCS-CMS 684435 — JUNE 24, 2024, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ozempencom-684435-06242024#:~:text=WARNING%20LETTER&text=As%20discussed%20below%2C%20FDA%20has,new%20drugs%20and%20misbranded%20drugs.>

THE PARTIES

10. Plaintiff NNAS is a corporation organized and existing under the laws of the Kingdom of Denmark and has its principal place of business in Bagsværd, Denmark.

11. Novo Nordisk developed the Ozempic[®], Wegovy[®], and Rybelsus[®] medicines.

12. NNAS has granted to Plaintiff NNI exclusive rights to market, advertise, promote, offer for sale, and sell Ozempic[®], Wegovy[®], and Rybelsus[®] medicines in the United States.

13. Plaintiff NNI is a corporation organized and existing under the laws of Delaware and has its principal place of business in Plainsboro, New Jersey.

14. NNI promotes, offers, and/or sells Novo Nordisk's Ozempic[®], Wegovy[®], and Rybelsus[®] medicines throughout the United States, including in this District.

15. Defendant American Health Center, Ltd. is an Illinois limited liability company with a business address at 1640 N Arlington Heights Road, Suite 101, Arlington Heights, Illinois 60004.

16. Defendant sells and promotes compounded drug products that purport to contain semaglutide, but that have not been approved by the FDA ("Unapproved Compounded Drugs").

17. Defendant falsely claims, or otherwise misleadingly suggests, that its Unapproved Compounded Drugs are the same as or equivalent to Ozempic[®] and Wegovy[®] medicines.

JURISDICTION AND VENUE

18. The Court has subject matter jurisdiction over the Lanham Act causes of action pleaded herein pursuant to 15 U.S.C. § 1121 and 28 U.S.C. § 1338(a). The Court has supplemental jurisdiction over the state and common law causes of action pleaded herein pursuant to 28 U.S.C. § 1338(b).

19. Defendant is subject to personal jurisdiction in this Court because Defendant is registered in Illinois and has a principal place of business in Illinois.

20. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendant operates in this District, manufactures and/or sells its compounded drug products that purport to contain semaglutide in this District, and otherwise conducts business in this District.

**NOVO NORDISK'S FDA-APPROVED SEMAGLUTIDE MEDICINES AND
OZEMPIC[®], WEGOVY[®], AND RYBELSUS[®] TRADEMARKS**

21. Plaintiffs use the trademarks “Ozempic,” “Wegovy,” and “Rybelsus” to identify and promote the FDA-approved Ozempic[®], Wegovy[®], and Rybelsus[®] medicines. The Ozempic[®], Wegovy[®], and Rybelsus[®] medicines are sold and marketed in the United States by NNAS’s indirect, wholly-owned subsidiary, NNI.

22. The Ozempic[®] medicine is indicated for adults with type 2 diabetes to improve blood sugar (glucose), along with diet and exercise.

23. The Ozempic[®] medicine also lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes and known heart disease.

24. The Wegovy[®] medicine is indicated to reduce excess body weight and maintain weight reduction long term in adults and children aged ≥ 12 years with obesity, and some adults with overweight and weight-related medical problems, along with a reduced calorie diet and increased physical activity.

25. The Wegovy[®] medicine is also indicated, with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events such as “cardiovascular” death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.

26. The Rybelsus[®] medicine is indicated for adults with type 2 diabetes to improve blood sugar (glucose), along with diet and exercise.

27. The Ozempic[®], Wegovy[®], and Rybelsus[®] medicines have been extensively studied in clinical trials and are FDA-approved.

28. Each of the Ozempic[®], Wegovy[®], and Rybelsus[®] medicines has a unique safety and efficacy profile which is set forth in its respective product label.

29. The Ozempic[®], Wegovy[®], and Rybelsus[®] medicines are prescription-only medicines that should only be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional.

DEFENDANT'S SALE OF UNAPPROVED COMPOUNDED DRUGS

30. Novo Nordisk has not authorized Defendant to use its marks, has not provided Defendant with Novo Nordisk's FDA-approved semaglutide medicines, and does not sell the bulk semaglutide in Novo Nordisk's FDA-approved semaglutide medicines to any compounding pharmacies from which it may be sourcing its Unapproved Compounded Drugs.

31. Defendant markets and sells to patients Unapproved Compounded Drugs that purport to contain semaglutide and that are not approved by the FDA.

32. The FDA has not approved Defendant's Unapproved Compounded Drugs.

33. On information and belief, the Unapproved Compounded Drugs sold by Defendant are made by compounding pharmacies, which deliver them either directly to patients or to Defendant for administration or dispensing to patients.

34. The FDA defines compounding as a "practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient."²

² Human Drug Compounding, <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding>.

35. According to the FDA, “[c]ompounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”³

36. The FDA has further stated that compounded drugs “do not have the same safety, quality, and effectiveness assurances as approved drugs. Unnecessary use of compounded drugs unnecessarily exposes patients to potentially serious health risks.”⁴

37. As the FDA has explained, “[c]ompounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness. Compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug.”⁵

38. The process used to produce most “semaglutide” used in compounding is fundamentally different from the process used to produce the semaglutide in Novo Nordisk’s FDA-approved medicines. Novo Nordisk manufactures the semaglutide in its medicines, pursuant to its FDA approval, in yeast cells under a closely controlled multistep process that uses recombinant DNA technology. Most compounded “semaglutide,” however, uses a “semaglutide” manufactured via chemical synthesis. The fundamental differences between these processes have resulted in new impurities, higher levels of known impurities, immunogenicity concerns, and potential stability issues in tested samples of compounded “semaglutide.”⁶

³ Compounding Laws and Policies, <https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies>.

⁴ Compounding and the FDA: Questions and Answers, <https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>.

⁵ FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products, <https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded>.

⁶ Morten Hach *et al*, Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs, *Pharm. Res.*, (Oct. 8, 2024), *available at* <https://pubmed.ncbi.nlm.nih.gov/39379664/>.

39. The FDA has received reports of adverse events, some requiring hospitalization, related to overdoses from dosing errors associated with compounded “semaglutide” products.⁷ In several instances, patients mistakenly administered five to 20 times more than the intended dose of compounded “semaglutide.”

40. The FDA has stated that the containers and packaging (including multidose vials and prefilled syringes) used by compounders, the varying product concentrations, and the instructions accompanying the compounded drug contribute to the potential medical errors.

41. A publication from the Journal of the American Pharmacists Association also highlighted errors where patients accidentally self-administered doses of compounded “semaglutide” up to ten times greater than the intended amount.⁸

42. FDA has issued guidance on its “Concerns with Unapproved GLP-1 Drugs Used for Weight Loss,” which provides that: (1) “compounded drugs are not FDA-approved”; (2) use of compounded drugs containing “semaglutide” “can be risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality”; and (3) “FDA has received reports of adverse events related to compounded versions of semaglutide However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported.”⁹

⁷ FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products, <https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded>.

⁸ Joseph E. Lambson et al, *Administration Errors of Compounded Semaglutide Reported to a Poison Control Center—Case Series*, 63 J. Am. Pharmacists Ass’n 5 (2023), available at [https://www.japha.org/article/S1544-3191\(23\)00231-5/abstract](https://www.japha.org/article/S1544-3191(23)00231-5/abstract).

⁹ FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>.

**DEFENDANT'S FALSE ADVERTISING IN CONNECTION WITH ITS
SALE OF UNAPPROVED COMPOUNDED DRUGS**

43. Despite the foregoing, Defendant unlawfully advertises its Unapproved Compounded Drugs by making statements that describe the Ozempic[®] and Wegovy[®] medicines but that are false or misleading when in reference to Defendant's Unapproved Compounded Drugs.

44. Defendant has claimed or implied that its Unapproved Compounded Drugs have been subject to the clinical trials and studies associated with the FDA's review and approval of the Ozempic[®] and Wegovy[®] medicines.

45. Defendant has claimed or implied that its Unapproved Compounded Drugs contain the same semaglutide that the FDA evaluated in the context of reviewing and approving Novo Nordisk's new drug applications for the Ozempic[®], Wegovy[®], and Rybelsus[®] medicines.

46. Defendant has claimed or implied that its Unapproved Compounded Drugs are generic versions of the Wegovy[®] and Ozempic[®] medicines.


47. The claims in the preceding three paragraphs are false and misleading.

48. On information and belief, Defendant has made these false and misleading statements to attract customers and generate revenues and profits, including by passing off its Unapproved Compounded Drugs purporting to contain "semaglutide" as the Ozempic[®] and Wegovy[®] medicines or authorized variations of those medicines.

49. Novo Nordisk has no control over the nature, quality, or efficacy of the products sold by Defendant, including the Unapproved Compounded Drugs.

50. Defendant's false advertising is reflected in the paragraphs that follow as well as **Exhibit A** hereto.

51. Defendant falsely claims in its promotional materials that its Unapproved Compounded Drugs have been subjected to clinical studies and trials, such as those undergone by Novo Nordisk's Ozempic[®] and Wegovy[®] medicines.



52. In reality, Novo Nordisk’s FDA-approved medicines are the only drugs containing semaglutide to have been the subject of clinical trials. On information and belief, no such data exist for Defendant’s Unapproved Compounded Drugs.

53. The FDA has not reviewed, let alone approved, Defendant’s Unapproved Compounded Drugs and has not reviewed the “semaglutide” allegedly in Defendant’s Unapproved Compounded Drugs for safety, effectiveness, or quality.

54. Defendant also claims an association between its Unapproved Compounded Drugs and the Ozempic® and Wegovy® medicines by falsely indicating that the Ozempic® and Wegovy® medicines are merely “brand-name alternatives” to its Unapproved Compounded Drugs and by using #Ozempic, #wegovy, and similar hashtags in promoting its Unapproved Compounded Drugs:



American Health Center · [Follow](#)

June 17 · 🌐

Let us help you with you weight loss goals! Our patients are loving their semaglutide injections. American Health Center provides semaglutide starting at \$200; brand-name alternatives can cost over \$1,000.

Schedule your consultation today! (847) 255-7425

 Angelika Opiela, FNP

 Andriana Garbanzos, FNP-C

 Nisha Patel, M.D.

[#meded](#) [#primarycare](#) [#healthcare](#) [#medicine](#) [#patientcare](#) [#chicagolandmedicine](#)
[#weightlosssolutions](#) [#semaglutide](#) [#weightmanagement](#) [#arlingtonheights](#) [#ozempic](#)
[#healthfacts](#) [#ozempicweightloss](#) [#weightlosschicago](#)

**AMERICAN HEALTH CENTER**



SEMAGLUTIDE

Most Effective Medical Weight Loss

- Physician Weight loss Program
- Reduces Appetite
- Improves Cravings
- Burns fat & Boosts energy
- Safe & Effective
- Once Weekly Injections

 Like

 Comment

 Copy

 Share

 Write a comment...





American Health Center · Follow

September 30 at 9:01AM · 🌐

Let us help you with you weight loss goals! Our patients are loving their semaglutide injections. American Health Center provides semaglutide starting at \$200; brand-name alternatives can cost over \$1,000.

📅 Schedule your consultation today! (847) 255-7425

[#weightlossolutions](#) [#semaglutide](#) [#weightmanagement](#) [#arlingtonheights](#) [#ozempic](#) [#doctor](#) [#primarycare](#) [#healthcare](#) [#medicine](#) [#chicagolandmedicine](#) [#arlingtonheightsmedicine](#) [#ozempicweightloss](#) [#weightlosschicago](#) [#keto](#) [#fitness](#)... See more

Medical Weight Loss

Semaglutide

(Generic for Ozempic/Wegovy)



***Physician Weight loss Program**

- *Reduces Appetite**
- *Improves Cravings**
- *Burns fat & Boosts energy**
- *Safe & Effective**
- *Once Weekly Injections**

 AMERICAN HEALTH CENTER

 Like



 Comment

 Copy

 Share



Write a comment...





American Health Center · Follow

August 26 · 🌐

Let us help you with you weight loss goals! Our patients are loving their semaglutide injections. American Health Center provides semaglutide starting at \$200; brand-name alternatives can cost over \$1,000.

📞 Schedule your consultation today! (847) 255-7425

👩 Angelika Opiela, FNP
👩 Andriana Garbanzos, FNP-C
👩 Nisha Patel, M.D.

#healthcare #medicine #chicagolandmedicine #wellnessinfusion #ivmedicine
#annualhealthvisit #annualcheckup #chicagomedicine #wellnessvisit #healthandwellness
#arlingtonheights #arlingtonheightsmedicine #weightlossolutions #semaglutide
#weightmanagement #arlingtonheights #ozempic #healthcare #medicine #ozempicweightloss
#weightlosschicago #keto #fitnessjourney#semaglutideweightloss #northshoremoms
#chicagonorthshoremoms #glenviewil #mountprospectil #parkridgeil #barringtonil #palatineil



Semaglutide

(Generic for Ozempic/Wegovy)

Medical Weight Loss

- *Physician Weight loss Program
- *Reduces Appetite
- *Improves Cravings
- *Burns fat & Boosts energy
- *Safe & Effective
- *Once Weekly Injections

 AMERICAN HEALTH CENTER

👍 Like

💬 Comment

🔗 Copy

➦ Share



Write a comment...





American Health Center · Follow

January 26, 2023 · 🌐

Semaglutide makes your weight loss goals possible by lowering your blood sugar levels and increasing how full you feel after eating.

American Health Center provides dose-dependent pricing for semaglutide, starting at \$125. Brand-name alternatives can cost over \$1,000 per month.

Schedule an appointment with American Health today to learn if semaglutide is right for you!

📞 (847) 255-7425

🌐 <https://americanhealthcenterltd.com/contact-us>

👩 Angelika Opiela, FNP

👩 Nisha Patel, M.D.

#AmericanHealth #Illinois #Medical #Doctor #Doctors #Nurse #NursePractitioner #Patient #Health #Wellness #HealthAndWellness #Healthy #Healthcare #Medicine #TeleHealth #Semaglutide #WeightLoss #Ozempic #Wegovy



AMERICAN HEALTH CENTER

YOUR GOAL WEIGHT

is possible

Illustration of a person's feet standing on a white scale with a black dial.

AMERICANHEALTHCENTERLTD.COM

American Health Center

We are an independent primary care medical practice providing personaliz...

Learn more

👍 8

👍 Like

💬 Comment

🔗 Copy

➦ Share

 Write a comment...



55. To the contrary, Novo Nordisk is not directly or indirectly supplying semaglutide to Defendant or any compounding pharmacies from which it may be sourcing its Unapproved Compounded Drugs.

56. Moreover, the FDA has not reviewed the “semaglutide” allegedly in Defendant’s Unapproved Compounded Drugs for safety, effectiveness, or quality. Defendant has no basis to claim that its Unapproved Compounded Drugs are equivalent to the semaglutide in Novo Nordisk’s FDA-approved medications.

57. Defendant also advertises to its customers that its Unapproved Compounded Drugs are “generic for Ozempic/Wegovy”:



American Health Center · [Follow](#)

October 7 at 9:01 AM · 🌐



We provide a Physician Weight loss Program with Semaglutide which is generic for Ozempic/Wegovy.

- *Reduces Appetite
- *Improves Cravings
- *Burns fat & Boosts energy
- *Safe & Effective
- *Once Weekly Injections

📞 Call or text us to schedule (847) 255-7425

[#doctor](#) [#primarycare](#) [#healthcare](#) [#medicine](#) [#chicagolandmedicine](#) [#wellnessinfusion](#)
[#ivmedicine](#) [#chicagomedicine](#) [#wellnessvisit](#) [#healthandwellness](#) [#arlingtonheightsmedicine](#)
[#weightlosssolutions](#) [#semaglutide](#) [#weightmanagement](#) [#arlingtonheights](#) [#ozempic](#)
[#ozempicweightloss](#) [#weightlosschicago](#) [#keto](#) [#fitnesssjourney](#) [#dexta](#)
[#semaglutideweightloss](#) [#northshoremoms](#) [#chicagonorthshoremoms](#) [#glenviewil](#)
[#mountprospectil](#) [#parkridgeil](#) [#barringtonil](#) [#palatineil](#)



American Health Center · Follow

February 16, 2023 · 🌐

...

❓ What is semaglutide?

Semaglutide is the generic of Ozempic® or Wegovy®. It lowers your blood sugar levels and increases how full you feel after eating.

❓ How much does it cost?

The medication starts at \$150 (as of 3/1) depending on the dose.

❓ What are American Health Center patients saying about semaglutide?

"Semaglutide has given me hope that I can actually lose the weight!"

Get in touch with American Health Center to learn more about semaglutide!

📞 (847) 255-7425

🌐 <https://americanhealthcenterltd.com/contact>

👩 Angelika Opiela, FNP

👩 Nisha Patel, M.D.

👩 Andriana Garbanzos, FNP-C

#AmericanHealth #Illinois #Medical #Doctor #Doctors #Nurse #NursePractitioner #Patient #Health #Wellness #HealthAndWellness #Healthy #Healthcare #Medicine #TeleHealth #Semaglutide #Ozempic #Wegovy #WeightLoss #Testimonial



American Health Center

Doctor

Learn more

  17

1 share

 Like

 Comment

 Copy

 Share

 Write a comment...



American Health Center · Follow

August 5 · 🌐

Let us help you with you weight loss goals! Our patients are loving their semaglutide injections. American Health Center provides semaglutide starting at \$200; brand-name alternatives can cost over \$1,000.

📞 Schedule your consultation today! (847) 255-7425

#doctor #primarycare #healthcare #medicine #chicagolandmedicine #chicagomedicine #healthandwellness #arlingtonheights #arlingtonheightsmedicine #weightlosssolutions #semaglutide #weightmanagement #arlingtonheights #ozempic #doctor #primarycare #healthcare #medicine #chicagolandmedicine #arlingtonheightsmedicine #ozempicweightloss #weightlosschicago #keto #fitnesssjourney #dexta #semaglutideweightloss #northshoremoms #chicagonorthshoremoms #glenviewil #mountprospectil #parkridgeil #barringtonil #palatineil

Semaglutide
(Generic for Ozempic/Wegovy)

Medical Weight Loss

- *Physician Weight loss Program
- *Reduces Appetite
- *Improves Cravings
- *Burns fat & Boosts energy
- *Safe & Effective
- *Once Weekly Injections

AMERICAN HEALTH CENTER

👍 Like

💬 Comment

🔗 Copy

➦ Share

58. A “generic” in the context of prescription drugs refers to a complete medicine that concluded a specific FDA review process addressing important attributes of the drug, like safety and efficacy. The FDA has not approved any generic versions of Defendant’s Unapproved

Compounded Drugs. It is therefore false for Defendant to advertise its Unapproved Compounded Drugs as a generic version of the Ozempic® or Wegovy® medicines.

59. On information and belief, Defendant has engaged and continues to engage in these unlawful practices to attract customers and generate revenues and profits.

60. Defendant's false and misleading statements and practices are likely to cause mistake and deception in the marketplace.

61. Defendant's false and misleading marketing is also likely to expose patients to unnecessary risks. Patients who mistakenly believe Defendant to be offering Novo Nordisk's FDA-approved medicines, or equivalent thereto, are unlikely to understand the unique risks associated with, or the lack of clinical trials or testing establishing the safety and effectiveness of, Defendant's Unapproved Compounded Drugs.¹⁰

62. On information and belief, unless enjoined by this Court, Defendant will continue to falsely advertise its products as being equivalent to or associated with the Ozempic® and Wegovy® medicines, all in violation of Plaintiffs' rights.

FIRST CAUSE OF ACTION

False and Misleading Advertising and Promotion in Violation of 15 U.S.C. § 1125(a)(1)(B)

63. Plaintiffs reallege and incorporate each allegation in the preceding paragraphs of this Complaint as though fully set forth here.

64. Defendant's practices, as described in this Complaint, constitute unfair competition and false advertising in violation of Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).

¹⁰ See, e.g., Dozens Say They Lost Eyesight After Routine Surgery Using Compounded Pharmacy Drugs, WFAA, <https://www.wfaa.com/article/news/do-not-publish-yet/287-5f002ed3-e110-4063-9959-a2e5f54b5097> (reporting mistaken belief of patient taking a compounded drug that "every pill you take, every shot you take is tested.").

65. Defendant has violated the Lanham Act by using false or misleading descriptions of fact and false or misleading representations of fact in its commercial advertising or promotion that misrepresent the nature, characteristics, and/or qualities of Defendant's business practices and products, as set forth above.

66. Defendant has also engaged in other false or misleading advertising and promotion intended to assure patients that Defendant's practices are lawful. On information and belief, Defendant provides patients who purchase Defendant's Unapproved Compounded Drugs (or whom Defendant is trying to persuade to purchase its drugs) information that makes false or misleading statements, including those described herein and in the exhibits hereto.

67. The above-described acts of Defendant, if not enjoined by this Court, are likely to deceive members of the general public.

68. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs.

69. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

70. By reason of Defendant's acts as alleged above, Plaintiffs have suffered and will continue to suffer injuries, including injury to Plaintiffs' business reputation.

71. Because Plaintiffs' remedies at law are not adequate to compensate for all the injuries inflicted by Defendant, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief requiring Defendant to cease its false and misleading advertising and promotion and unfair competitive practices.

72. Because the above-described acts of Defendant are willful, the Court should award disgorgement of Defendant's profits (enhanced at the Court's discretion), treble damages, and costs under 15 U.S.C. § 1117 to Plaintiffs.

73. This case is exceptional, making Plaintiffs eligible for an award of attorneys' fees under 15 U.S.C. § 1117.

SECOND CAUSE OF ACTION

Unfair Competition in Violation of the Common Law

74. Plaintiffs reallege and incorporate each allegation in in the preceding paragraphs of this Complaint as though fully set forth here.

75. The above-described acts of Defendant constitute common law unfair competition.

76. The above-described acts of Defendant unfairly and wrongfully exploit Plaintiffs' trademark, goodwill, and reputation.

77. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

78. Because Plaintiffs' remedies at law are not adequate to compensate for the injuries inflicted by Defendant, the Court should enter preliminary and permanent injunctive relief, in addition to awarding disgorgement of Defendant's profits and corrective advertising costs to Plaintiffs.

THIRD CAUSE OF ACTION

**Deceptive Trade Practices in Violation of
815 Ill. Comp. Stat. Ann. 510/1 *et seq.***

79. Plaintiffs reallege and incorporate each allegation in the preceding paragraphs of this Complaint as though fully set forth here.

80. Defendant's practices, as described in this Complaint, constitute deceptive trade practices in violation of 815 Ill. Comp. Stat. Ann. 510/2(a).

81. The above-described acts of Defendant have violated the Illinois Uniform Deceptive Trade Practices Act by:

- a. causing likelihood of confusion or of misunderstanding as to source, sponsorship, approval, certification, affiliation, connection, or association of goods or services, 510/2(a)(2) & (3); and
- b. representing that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have, 510/2(a)(5).

82. The above-described acts of Defendant constitute unfair methods of competition, and unconscionable, deceptive, or unfair acts or practices in violation of the laws of the State of Illinois.

83. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs.

84. By reason of Defendants' acts, Plaintiffs' remedy at law is not adequate to compensate for the injuries inflicted by Defendants. Accordingly, the Court should enter preliminary and permanent injunctive relief, in addition to awarding disgorgement of Defendant's profits and corrective advertising costs to Plaintiffs.

REQUEST FOR RELIEF

WHEREFORE, Plaintiffs request judgment against Defendant as follows:

1. That the Court enter a judgment against Defendant that Defendant has:
 - a. Engaged in false and misleading advertising and promotion, in violation of 15 U.S.C. § 1125(a);
 - b. Engaged in unfair competition under the common law and violated the Illinois Uniform Deceptive Trade Practices Act, 815 Ill. Comp. Stat. Ann. 510/1 et seq.
2. That the Court find that each of the above acts was willful.
3. That the Court preliminarily and permanently enjoin and restrain Defendant and its agents, servants, employees, successors, and assigns, and all other persons acting in concert with or in conspiracy with or affiliated with Defendant, from:
 - a. using the Ozempic[®] and Wegovy[®] marks, including (i) use in any manner that is likely to cause confusion or mistake, to deceive, or otherwise infringe Novo Nordisk's rights in the Ozempic[®] and Wegovy[®] marks, or (ii) use in connection with the advertising, marketing, sale, or promotion of any Unapproved Compounded Drugs; and,
 - b. advertising, stating, or suggesting that any Unapproved Compounded Drugs, including any Unapproved Compounded Drugs that either are available, directly or indirectly, from or through Defendant or the use of which or access to which is facilitated by, or with the involvement of, Defendant:
 - i. are, or contain, genuine or authentic Novo Nordisk Ozempic[®] or Wegovy[®] medicines;
 - ii. are sponsored by or associated with Novo Nordisk;
 - iii. are approved by the FDA; have been reviewed by the FDA for safety, effectiveness, or quality; or have been demonstrated to the FDA to be safe or effective for their intended use;

- iv. achieve or have been shown or proven to achieve certain therapeutic results, effects, or outcomes, including by relying on or making reference to clinical trial results for Novo Nordisk's medicines;
- v. achieve or have been shown or proven to achieve therapeutic results, effects, or outcomes similar or identical to Novo Nordisk's medicines and/or are interchangeable with or equivalent to genuine Novo Nordisk medicines;
- vi. are associated or connected with Novo Nordisk or Novo Nordisk's medicines; or
- vii. contain any ingredient (including but not limited to semaglutide) that is supplied by Novo Nordisk, is approved by the FDA, or is the same as any ingredient in any Novo Nordisk medicine.

- c. engaging in any unfair competition with Plaintiffs; and/or
- d. engaging in any deceptive acts or practices.

4. That the Court require Defendant to disclose conspicuously and prominently in any public-facing materials for any Unapproved Compounded Drugs, including all advertising, marketing, and promotional materials, that: (a) the Unapproved Compounded Drugs are compounded drugs that have not been approved by the FDA; have not been reviewed by the FDA for safety, effectiveness, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use; (b) the processes by which the compounded drugs are manufactured have not been reviewed by the FDA; and (c) FDA-approved medicines containing semaglutide are available.

5. That the Court award Plaintiffs monetary relief in the form of disgorgement of Defendant's profits for Defendant's false advertising and unfair competition and that this monetary

relief be trebled due to Defendant's willfulness, in accordance with the provisions of 15 U.S.C. § 1117 and any applicable state laws.

6. That the Court award disgorgement of Defendant's profits resulting from Defendant's infringement of Plaintiffs' rights and by means of Defendant's unfair competition to Plaintiffs.

7. That the Court order Defendant to account for and disgorge to Plaintiffs all amounts by which Defendant has been unjustly enriched by reason of Defendant's unlawful actions.

8. That the Court award Plaintiffs punitive damages by reason of Defendant's willful unlawful actions.

9. That the Court award Plaintiffs pre-judgment and post-judgment interest on all damages.

10. That the Court award Plaintiffs their reasonable attorneys' fees pursuant to 15 U.S.C. § 1117 and any other applicable provision of law.

11. That the Court award Plaintiffs the costs of suit incurred herein.

12. That the Court award such other or further relief as the Court may deem just and proper.

December 12, 2024

Respectfully submitted,

By: /s/ Suyash Agrawal

Suyash Agrawal

Robert Aguirre

MASSEY & GAIL LLP

50 E Washington Street, Suite 400

Chicago, Illinois 60602

sagrawal@masseygail.com

raguirre@masseygail.com

Attorneys for Plaintiffs
NOVO NORDISK A/S and
NOVO NORDISK INC.